Role of acquired von Willebrand syndrome in the development of bleeding complications in patients treated with Impella RP devices

• Published in: Scientific reports 2021-12, Vol.11 (1), p.23722-23722, Article 23722
• Main Authors: Oezkur, Mehmet, Reda, Sara, Rühl, Heiko, Theuerkauf, Nils, Kreyer, Stefan, Duerr, Georg Daniel, Charitos, Efstratios, Silaschi, Miriam, Medina, Marta, Zimmer, Sebastian, Putensen, Christian, Treede, Hendrik
• Format: Article
• Language: English
• Subjects: 692/4019/2773; 692/499; 692/699/75/230; Aged; Anticoagulants; Anticoagulants - administration & dosage; Antigens; Automation; Bleeding; Blood Coagulation - drug effects; Blood Coagulation Tests; Blood platelets; Cardiology; Consortia; Endothelium; Extracorporeal membrane oxygenation; Female; Heart; Heart Failure - etiology; Heart Failure - therapy; Heart surgery; Heart-Assist Devices; Hemorrhage - etiology; Hemorrhage - therapy; Heparin; Hospitals; Humanities and Social Sciences; Humans; Intensive care; Intravenous administration; Laboratories; Male; Middle Aged; Mortality; multidisciplinary; Partial Thromboplastin Time; Patients; Plasma; Pumps; Science; Science (multidisciplinary); Thromboplastin; Treatment Outcome; Veins & arteries; Ventricle; von Willebrand Diseases - complications; von Willebrand Diseases - etiology; von Willebrand Diseases - therapy
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-02833-8

Axial flow pumps are standard treatment in cases of cardiogenic shock and high-risk interventions in cardiology and cardiac surgery, although the optimal anticoagulation strategy remains unclear. We evaluated whether laboratory findings could predict bleeding complications and acquired von Willebrand syndrome (avWS) among patients who were treated using axial flow pumps. We retrospectively evaluated 60 consecutive patients who received Impella devices (Impella RP: n = 20, Impella CP/5.0: n = 40; Abiomed Inc., Danvers, USA) between January 2019 and December 2020. Thirty-two patients (53.3%) experienced major or fatal bleeding complications (Bleeding Academic Research Consortium score of > 3) despite intravenous heparin being used to maintain normal activated partial thromboplastin times (40–50 s). Extensive testing was performed for 28 patients with bleeding complications (87.5%). Relative to patients with left ventricular support, patients with right ventricular support were less likely to develop avWS (87.5% vs. 58.8%, p = 0.035). Bleeding was significantly associated with avWS (odds ratio [OR]: 20.8, 95% confidence interval [CI]: 3.3–128.5; p = 0.001) and treatment duration (OR: 1.3, 95% CI 1.09–1.55; p = 0.003). Patients with avWS had longer Impella treatment than patients without avWS (2 days [1–4.7 days] vs. 7.3 days [3.2–13.0 days]). Bleeding complications during Impella support were associated with avWS in our cohort, while aPTT monitoring was not sufficient to prevent bleeding complications. A more targeted anticoagulation monitoring might be needed for patients who receive Impella devices.